Drug Profile
AMP 110
Alternative Names: AMP-110Latest Information Update: 05 Aug 2021
Price :
$50
*
At a glance
- Originator Amplimmune
- Developer AstraZeneca; Daiichi Sankyo Company
- Class Antirheumatics; Recombinant fusion proteins
- Mechanism of Action T cell activation inhibitors; Th1 cell inhibitors; Th17 cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Rheumatoid arthritis
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in USA (IV, Infusion)
- 29 Nov 2016 AMP 110 is still in phase I trials for Rheumatoid arthritis in USA
- 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in USA (IV, Infusion)